| scholarly article | Q13442814 |
| P50 | author | Lucjan S Wyrwicz | Q73534705 |
| P2093 | author name string | H Xiong | |
| S H Park | |||
| E Van Cutsem | |||
| M-H Ryu | |||
| Y-J Bang | |||
| J Taieb | |||
| M Lichinitser | |||
| J Hong | |||
| S-E Al-Batran | |||
| M Alsina | |||
| K-W Lee | |||
| M H Moehler | |||
| H-C Chung | |||
| N Boku | |||
| M Schenker | |||
| I Conti | |||
| E Yañez Ruiz | |||
| L Evesque | |||
| R Hallwachs | |||
| P2860 | cites work | Advanced gastric cancer: Current treatment landscape and future perspectives | Q26764934 |
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis | Q33818002 | ||
| Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance | Q37457628 | ||
| Chemotherapy for advanced gastric cancer. | Q38604012 | ||
| PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. | Q38630412 | ||
| Japanese gastric cancer treatment guidelines 2014 (ver. 4). | Q39656427 | ||
| Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients | Q40581214 | ||
| Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial | Q46287609 | ||
| Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Q47745009 | ||
| PD-L1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer | Q49968394 | ||
| Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial | Q53837214 | ||
| Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? | Q54970742 | ||
| Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status. | Q55307728 | ||
| Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† | Q61867571 | ||
| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial | Q89029141 | ||
| P433 | issue | 10 | |
| P921 | main subject | phase III clinical trial | Q42824827 |
| P304 | page(s) | 2052-2060 | |
| P577 | publication date | 2018-10-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 | |
| P478 | volume | 29 |
| Q92165067 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data |
| Q64915202 | Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe? |
| Q61800297 | Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial |
| Q94526290 | Cautious optimism-the current role of immunotherapy in gastrointestinal cancers |
| Q90321355 | Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies |
| Q98177944 | Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer |
| Q89602407 | Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis |
| Q59789596 | Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies |
| Q98289189 | Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis |
| Q96617755 | Correlations Between Progression-free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-analysis |
| Q96132801 | Current Molecular Targeted Agents for Advanced Gastric Cancer |
| Q58594584 | Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies |
| Q90643923 | Delivery rate of patients with advanced gastric cancer to third-line chemotherapy and those patients' characteristics: an analysis in real-world setting |
| Q91868485 | Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis |
| Q98164819 | Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials |
| Q64288065 | Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer |
| Q90600978 | Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1 |
| Q90019582 | Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS |
| Q64249283 | How to better select patients with advanced gastric cancer for immunotherapy |
| Q64939865 | Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer. |
| Q92636993 | Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis |
| Q97643978 | Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives |
| Q64249000 | Immune checkpoint inhibitors in esophagogastric cancer: still a long way to go |
| Q93129314 | Immune checkpoint inhibitors of PD-L1 as cancer therapeutics |
| Q61799417 | Immunotherapeutic advances in gastrointestinal malignancies |
| Q91942638 | Immunotherapy in Esophagogastric Adenocarcinoma |
| Q93135012 | Late-line treatment in metastatic gastric cancer: today and tomorrow |
| Q89510259 | New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice? |
| Q59136693 | New drug developments in metastatic gastric cancer |
| Q64990976 | Next-generation sequencing and biomarkers for gastric cancer: what is the future? |
| Q92240594 | Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights |
| Q98466119 | Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction? |
| Q89677679 | Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis |
| Q93024218 | Optimal management of gastroesophageal junction cancer |
| Q96770049 | Pancreatic cancer |
| Q64073956 | Pembrolizumab in advanced gastric cancer: pioneering or prosaic? |
| Q90264677 | Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial |
| Q90064455 | Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study |
| Q96155607 | Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers |
| Q94547576 | Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer |
| Q92358620 | Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens |
| Q94546944 | Role of Systemic Treatment for Advanced/Metastatic Gastric Carcinoma in the Third-Line Setting: A Bayesian Network Analysis |
| Q90333943 | Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers |
| Q90087481 | The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma |
| Q61812340 | Therapeutic Potential of Natural Killer Cells in Gastric Cancer |
| Q91725221 | Third-line systemic treatment in advanced/metastatic gastric cancer: a comprehensive review |
| Q90300273 | Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis |
Search more.